Solubility and Stability Enhanced Oral Formulations for the Anti-Infective Corallopyronin A.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Krome, Anna KBecker, Tim
Kehraus, Stefan
Schiefer, Andrea
Steinebach, Christian
Aden, Tilman
Frohberger, Stefan J
López Mármol, Álvaro
Kapote, Dnyaneshwar
Jansen, Rolf
Chaverra-Muñoz, Lillibeth
Hübner, Marc P
Pfarr, Kenneth
Hesterkamp, Thomas
Stadler, Marc
Gütschow, Michael
König, Gabriele M
Hoerauf, Achim
Wagner, Karl G
Issue Date
2020-11-18
Metadata
Show full item recordAbstract
Novel-antibiotics are urgently needed to combat an increase in morbidity and mortality due to resistant bacteria. The preclinical candidate corallopyronin A (CorA) is a potent antibiotic against Gram-positive and some Gram-negative pathogens for which a solid oral formulation was needed for further preclinical testing of the active pharmaceutical ingredient (API). The neat API CorA is poorly water-soluble and instable at room temperature, both crucial characteristics to be addressed and overcome for use as an oral antibiotic. Therefore, amorphous solid dispersion (ASD) was chosen as formulation principle. The formulations were prepared by spray-drying, comprising the water-soluble polymers povidone and copovidone. Stability (high-performance liquid chromatography, Fourier-transform-infrared spectroscopy, differential scanning calorimetry), dissolution (biphasic dissolution), and solubility (biphasic dissolution, Pion's T3 apparatus) properties were analyzed. Pharmacokinetic evaluations after intravenous and oral administration were conducted in BALB/c mice. The results demonstrated that the ASD formulation principle is a suitable stability- and solubility-enhancing oral formulation strategy for the API CorA to be used in preclinical and clinical trials and as a potential market product.Citation
Pharmaceutics. 2020 Nov 18;12(11):1105. doi: 10.3390/pharmaceutics12111105.Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.Publisher
MDPIJournal
PharmaceuticsPubMed ID
33217948Type
ArticleLanguage
enISSN
1999-4923ae974a485f413a2113503eed53cd6c53
10.3390/pharmaceutics12111105
Scopus Count
The following license files are associated with this item:
- Creative Commons
Related articles
- In Vitro-In Vivo Relationship in Mini-Scale-Enabling Formulations of Corallopyronin A.
- Authors: Becker T, Krome AK, Vahdati S, Schiefer A, Pfarr K, Ehrens A, Aden T, Grosse M, Jansen R, Alt S, Hesterkamp T, Stadler M, Hübner MP, Kehraus S, König GM, Hoerauf A, Wagner KG
- Issue date: 2022 Aug 9
- Spray Encapsulation as a Formulation Strategy for Drug-Based Room Temperature Ionic Liquids: Exploiting Drug-Polymer Immiscibility to Enable Processing for Solid Dosage Forms.
- Authors: Stocker MW, Healy AM, Ferguson S
- Issue date: 2020 Sep 8
- Spray drying ternary amorphous solid dispersions of ibuprofen - An investigation into critical formulation and processing parameters.
- Authors: Ziaee A, Albadarin AB, Padrela L, Faucher A, O'Reilly E, Walker G
- Issue date: 2017 Nov
- Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier.
- Authors: Ghanavati R, Taheri A, Homayouni A
- Issue date: 2017 Mar 1
- A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
- Authors: Caron V, Tajber L, Corrigan OI, Healy AM
- Issue date: 2011 Apr 4